Aurinia Pharmaceuticals (AUPH): EOP2 Meeting Results Were Better Than Could Have Been Hoped For - HC Wainwright

Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 7c; Initiates Talks with Japan for Voclosporin Phase 1

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14).

Aurinia plans to initiate a single, Phase 3 clinical trial (AURORA) whose design is consistent with that of the ongoing AURA clinical trial. The totality of data from both... More